RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine ...
The First FDA-Approved RSV Vaccine for People 60 Years and Older. AREXVY protects against lung and lower airway infection caused by respiratory syncytial virus (RSV).
Early Safety Findings Among Persons Aged ≥60 Years ...
Jul 11, 2024 · In May 2023, the Food and Drug Administration (FDA) licensed Arexvy and Abrysvo vaccines for prevention of respiratory syncytial virus (RSV) lower respiratory tract …
US FDA approves expanded age indication for GSK's ...
Jun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, …
GSK presents positive data for Arexvy, its respiratory syncytial …
Oct 8, 2024 · Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain …
GSK's Arexvy dominates RSV market ahead of new competition
May 1, 2024 · GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms. Even with the threat of a potential new competitor in the …
GSK reports blockbuster sales RSV shot Arexvy in race vs.
Jan 31, 2024 · GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023, compared to $890 million for Pfizer's Abrysvo. But GSK says the market battle has just begun.
GSK sales of RSV vaccine stay strong, beating forecast
Jan 31, 2024 · GSK, meanwhile, aims to build its market lead, and is seeking a expanded approval of Arexvy in adults aged 50 to 59 in the U.S., Europe and Japan. The company …
AREXVY | FDA - U.S. Food and Drug Administration
Jun 2, 2023 · Approval History, Letters, Reviews, and Related Documents - AREXVY. For active immunization for the prevention of lower respiratory tract disease caused by respiratory …
Arexvy received a marketing authorisation valid throughout the EU on 6 June 2023. Further information on Arexvy can be found on the Agency’s website: …
Arexvy | European Medicines Agency (EMA)
Arexvy is a vaccine used to protect adults 60 years of age and older against lower respiratory tract disease (LRTD, diseases of the lungs such as bronchitis or pneumonia) caused by respiratory …